Lundbeck

On Friday, Lundbeck announced that they are investing 10 million euros to buy a stake in Biotie Therapies Corp, Lundbeck’s partner on the investigational alcohol dependence drug Selincro. The investment signifies 4.6% of Biotie’s total equity capital, and a 25% premium to the Finnish biotech’s share price on September 6. In association with the agreement,

Lundbeck announced yesterday that they are axing roughly 600 employees in Europe from their sales teams as a result of the harsh environment and generic competition to their top antidepressant Cipralex/Lexapro. The Danish organisation declared that the reorganisation is required because they need to establish “a more flexible commercial infrastructure with respect to detailing to